Supplementary Figure 1 from Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells

Puntos clave

• Expression profiling reveals detectable levels of GPC2 alongside GD2 across examined retinoblastoma specimens, confirming their presence on tumor cells.
• Assessment using patient tumor samples and established cell lines characterizes target antigen distribution across intraocular and metastatic disease.
• Findings support evaluating GPC2-directed CAR T cell therapies against retinoblastoma, though further preclinical validation in disease models is needed.